Tina Liedtky: Thermo Fisher Scientific Launches New Test to Help Guide Tacrolimus Dosing
Tina Liedtky, President of the Transplant Diagnostics Division at Thermo Fisher Scientific, shared a post on LinkedIn:
“In transplant medicine, every patient is unique. And healthcare teams need tools that enable them to provide personalized care.
To this end, I am excited to share that, today, Thermo Fisher Scientific launched a new laboratory developed test to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug that can help lower the risk of transplant rejection.
The right tacrolimus dose will vary from patient to patient.
With the new TacroType Pharmacogenetic Test, clinicians can better understand how their patient is likely to metabolize tacrolimus and respond to certain therapies.
This pharmacogenetic information is invaluable.
Learn more about what the new TacroType Pharmacogenetic Test means for patient care by reading the press release.”
Stay updated with Hemostasis Today.
-
Jul 19, 2026, 06:28Estrogen-Associated VTE: From Real-World Evidence to the Biology of Persistent Thrombosis
-
Jul 19, 2026, 05:01Maissa El-Qendouci: Optimizing Iron Deficiency Diagnosis in TAVR
-
Jul 19, 2026, 04:39Saoud Hassan: Identifying Monocytic Precursors Under the Microscope
-
Jul 19, 2026, 04:23Iris van Moort: Expert Insights on Pediatric Hemostasis Diagnostics at ISTH 2026
-
Jul 19, 2026, 04:09Er. Subodh Grewal: How Platelet Histograms Support Hematology Diagnosis
-
Jul 19, 2026, 03:53Serhii Pelishenko: Current Evidence on Kaolin and Chitosan Dressings
-
Jul 18, 2026, 23:52Chinua Onyebuchi: Applications Now Open for the European Stroke Master Programme
-
Jul 18, 2026, 22:43Exploring the Ultra-Late Window for Stroke Treatment – International Journal of Stroke
-
Jul 18, 2026, 21:38Swastik Sharma Deviprasad Bhat: A One-Minute Guide to Recognizing Stroke